Side Effects of Drugs Annual -

Side Effects of Drugs Annual (eBook)

A worldwide yearly survey of new data in adverse drug reactions

Jeffrey K Aronson (Herausgeber)

eBook Download: PDF | EPUB
2014 | 1. Auflage
1056 Seiten
Elsevier Science (Verlag)
978-0-444-62636-3 (ISBN)
Systemvoraussetzungen
Systemvoraussetzungen
285,00 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.


  • Provides a critical yearly survey of new data and trends
  • Special reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors

  • The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading. Provides a critical yearly survey of new data and trends Special reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors

    Contributors


    Lise Aagaard, PhD, HD(O) (Chapter 1)

    Institute of Public Health, Clinical Pharmacology, Faculty of Health Sciences, University of Southern Denmark, JB Winsløws Vej 19, 2. 5000 Odense C, Denmark. E-mail: laagaard@health.sdu.dk.

    Jeffrey K. Aronson, MA, MBChB, DPhil, FRCP, FBPharmacolS, FFPM (Hon) (Chapters 6, 8, 24, 34, 37, 41, 45)

    University Department of Primary Care Health Sciences, New Radcliffe House, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK. E-mail: jeffrey.aronson@phc.ox.ac.uk.

    Charlotte I.S. Barker, BMBCh (Chapter 29)

    Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George’s, University of London, Cranmer Terrace, London SW17 0RE, and Faculty of Medicine, Imperial College, London, UK. E-mail: cisbark4444@doctors.org.uk.

    Corrado Blandizzi, MD, PhD (Chapter 36)

    Division of Pharmacology & Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy. E-mail: c.blandizzi@gmail.com.

    Andrew Byrne, BA, MB BCh, BAO, MRCPsych, MMedSc (Chapter 5)

    St George's Park, Morpeth, Northumberland, NE61 2NU, UK.

    Santos Castañeda, MD, PhD (Chapter 40)

    Department of Rheumatology, IIS-Princesa, Hospital Universitario de La Princesa, c/ Diego de León 62, 28006-Madrid, Spain. E-mail: scastas@gmail.com.

    K. Chan, PhD, DSc, FSB, FCP, FRPS, FRSM (Chapter 48)

    Faculty of Pharmacy, The University of Sydney and National Institute of Complementary Medicine, University of Western Sydney, Locked Bag 1797, Penrith NSW 2571, Australia. E-mail: kelvin.chan@sydney.edu.au.

    John R. Charpie, MD, PhD (Chapter 17)

    Department of Pediatrics and Communicable Diseases, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. E-mail: jcharpie@med.umich.edu.

    Taylor A. Choi, PhD (Chapter 26)

    Chemical Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720. E-mail: tchoi@lbl.gov.

    N.H. Choulis, MD, PhD (Chapters 14, 49)

    University of Athens, PO Box 51173, 14510 Kifisia, Greece. E-mail: nicoly@otenet.gr.

    Steve S. Chung, MD (Chapter 7)

    Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. E-mail: steve.chung@dignityhealth.org.

    Jamie J. Coleman, MBChB, MA (Med Ed), MD, MRCP(UK) (Chapter 20)

    School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. E-mail: j.j.coleman@bham.ac.uk.

    Joan Costa, MD (Chapter 39)

    Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Ctra. de Canyet s/n, 08916 Badalona, Spain. E-mail: joan.costa.pages@gmail.com.

    D. Cowan, MBChB, PhD, MRCP (Glasgow) (Chapter 16)

    Department of Respiratory Medicine, Glasgow Royal Infirmary, 16 Alexander Parade, Glasgow, G31 2ER, UK. E-mail: douglas.cowan@otago.ac.nz.

    Anthony R. Cox, PhD (Chapter 20)

    School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. E-mail: a.r.cox@bham.ac.uk.

    Stephen Curran, BSc, MBChB, MMedSc, MRCPsych, PhD (Chapter 5)

    Fieldhead Hospital, South West Yorkshire Mental Health NHS Trust, Ouchthorpe Lane, Wakefield, WF1 3SP, UK. E-mail: s.curran@hud.ac.uk.

    Rinkoo Dalan, MBBS, FRCP(Edin), FAMS (Endocrinology) (Chapter 43)

    Department of Endocrinology, Tan Tock Seng Hospital, DUKE-NUS Graduate Medical School, National University of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. E-mail: rinkoo_dalan@ttsh.com.sg.

    S. Dittmann, MD, DScMed (Chapter 32)

    19 Hatzenporter Weg, 12681 Berlin, Germany. E-mail: sd.internat.immun.consult@t-online.de.

    Rif S. El-Mallakh, MD (Chapter 3)

    Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, MedCenter One, 501 E Broadway, Suite 340, Louisville, Kentucky 40202, USA. E-mail: rselma01@louisville.edu.

    M. Farré, MD (Chapter 39)

    Human Pharmacology and Neurosciences, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Parc de Salut Mar, Universitat Autònoma de Barcelona, Doctor Aiguader 88, 08003 Barcelona, Spain. E-mail: mfarre@imim.es.

    E. Flockton, MBChB, FRCA, FFICM (Chapter 10)

    Department of Critical Care, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK. E-mail: Elizabeth.Flockton@rlbuht.nhs.uk.

    Swaran J.S. Flora, PhD, FNASc (Chapter 22)

    Division of Pharmacology & Toxicology, Defence Research and Development Establishment, Jhansi Road, Gwalior 474002, India. E-mail: sjsflora@drde.drdo.in; sjsflora@gmail.com.

    Joshua M. Friedland-Little, MD (Chapter 17)

    Department of Pediatrics and Communicable Diseases, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. E-mail: jmfriedl@med.umich.edu.

    Luís Gales, PhD (Chapter 41)

    Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, and Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Rua do Campo Alegre 823, 4150-180 Porto, Portugal. E-mail: lgales@ibmc.up.pt.

    Jason C. Gallagher (Chapter 25)

    School of Pharmacy, Temple University, Philadelphia, PA 19140, USA. E-mail: jasoncg@temple.edu.

    Yonglin Gao, MD (Chapter 3)

    Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, MedCenter One, 501 E Broadway, Suite 340, Louisville, Kentucky 40202, USA. E-mail: ylgao001@louisville.edu.

    Tatsuya Gomi, MD, PhD (Chapter 46)

    Department of Radiology, Ohashi Medical Center, Toho University, Japan. E-mail: gomi@oha.toho-u.ac.jp.

    Wilson I. Gonsalves, MD (Chapter 35)

    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: Gonsalves.Wilson@mayo.edu.

    Makoto Hasegawa, MD (Chapter 46)

    Department of Radiology, Toho University Ohashi Medical Center, Japan. E-mail: ma12x-4c@din.or.jp.

    Yuichi Hattori, MD, PhD (Chapter 44)

    Department of Molecular and Medical Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. E-mail: yhattori@med.u-toyama.ac.jp.

    M.S. Jawahar, MD (Chapter 30)

    Department of Clinical Research, National Institute for Research in Tuberculosis, Mayor Sathiyamoorthy Salai, Chetput, Chennai 600 031, India. E-mail: shaheedjawahar@gmail.com.

    Lokesh Kumar Jha, MD (Chapter 38)

    Division of Gastroenterology and Hepatology, 983285 Nebraska Medical Center, Omaha, NE 68198-3285, USA. E-mail: lokesh.jha@unmc.edu.

    Jesco Kompardt, MD, FANZCA (Chapter 11)

    Anaesthetic Department, Joondalup Health Campus, Shenton Ave, Joondalup WA 6027, Australia. E-mail: jesco.kompardt@googlemail.com.

    Worapant Kriengsoontornkij, MD (Chapter 23)

    Division of Ambulatory Pediatrics, Department of Pediatrics, Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. E-mail: sikwr@yahoo.com.

    R. Latini, MD (Chapter 18)

    Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy. E-mail: roberto.latini@marionegri.it.

    Melvin K.S. Leow, MBBS, MMed(Int Med), MSc, PhD, FAMS, FACE, FACP, FRCP (Edin) (Chapter 43)

    Department of Endocrinology, Tan Tock Seng Hospital, Singapore. E-mail: mleowsj@massmed.org.

    J.M. Lestner, MBChB, MRes, MRCPCH (Chapter 29)

    Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK, and Faculty of Medicine, Imperial College, London, UK. E-mail: jlestner@nhs.net.

    M. Leuwer, MD (Chapters 10,...

    Erscheint lt. Verlag 4.3.2014
    Sprache englisch
    Themenwelt Schulbuch / Wörterbuch Lexikon / Chroniken
    Medizin / Pharmazie Allgemeines / Lexika
    Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
    Medizin / Pharmazie Pharmazie
    Technik
    ISBN-10 0-444-62636-0 / 0444626360
    ISBN-13 978-0-444-62636-3 / 9780444626363
    Haben Sie eine Frage zum Produkt?
    PDFPDF (Adobe DRM)
    Größe: 14,4 MB

    Kopierschutz: Adobe-DRM
    Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
    Details zum Adobe-DRM

    Dateiformat: PDF (Portable Document Format)
    Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

    Systemvoraussetzungen:
    PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
    eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
    Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
    Geräteliste und zusätzliche Hinweise

    Buying eBooks from abroad
    For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

    EPUBEPUB (Adobe DRM)
    Größe: 8,9 MB

    Kopierschutz: Adobe-DRM
    Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
    Details zum Adobe-DRM

    Dateiformat: EPUB (Electronic Publication)
    EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

    Systemvoraussetzungen:
    PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
    eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
    Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
    Geräteliste und zusätzliche Hinweise

    Buying eBooks from abroad
    For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

    Mehr entdecken
    aus dem Bereich